Atara Biotherapeutics, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $2M | ↓-95.1% | — | — | — |
| 2025-09-30 | $3M | ↓-91.4% | $-4M | ↑+80.4% | -103.5% |
| 2025-06-30 | $18M | ↓-38.6% | $2M | ↑+112.5% | 18.2% |
| 2025-03-31 | $98M | ↑+258.8% | $38M | ↑+219.7% | 39.5% |
| 2024-12-31 | $33M | ↑+670.3% | — | — | — |
| 2024-09-30 | $40M | ↑+1779.8% | $-22M | ↑+68.6% | -54.1% |
| 2024-06-30 | $29M | ↑+2892.7% | $-19M | ↑+73.2% | -63.7% |
| 2024-03-31 | $27M | ↑+2131.4% | $-32M | ↑+57.5% | -114.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$2M
↓-95.1% -$31M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ATRA Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyATRA Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics